Procter & Gamble Health Ltd. (PGHL) AI Stock Analysis

• Market Cap: ₹104.17B
• Dividend Yield: 2.94%
• Average Volume (3M): 727.00
• Price to Earnings (P/E): 34.7
• Beta (1Y): 0.48
• Revenue Growth: 2.37%
• EPS Growth: 23.22%
• Country: IN
• Employees: 1,336
• Sector: Consumer Defensive
• Sector Strength: 42
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): 39.87
• Shares Outstanding: 16,599,382
• 10 Day Avg. Volume: 509
• 30 Day Avg. Volume: 727
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: ₹7,160.00
• Price Target Upside: 14.09% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1

• Rating: 77 Outperform
• Price Target: ₹7,160.00 ▲(14.09% Upside)

Procter & Gamble Health Ltd. demonstrates strong financial performance with robust profitability and a solid balance sheet, contributing significantly to the overall score. The technical analysis indicates a strong upward trend, although caution is advised due to potential overbought conditions. The valuation suggests the stock may be slightly overvalued, but the dividend yield offers some compensation. Overall, the company is well-positioned, but investors should be mindful of valuation and technical indicators.

Procter & Gamble Health Ltd. Business Overview & Revenue Model

Company Description

Procter & Gamble Health Limited manufactures and markets pharmaceuticals and chemicals in India. It provides over-the-counter products, vitamins, minerals, and supplements. The company offers its products under the Polybion, Neurobion, Evion, Nasivion, Livogen, and Seven Seas brands. Procter & Gamble Health Limited also exports its pharmaceutical products to Sri Lanka, Nepal, Myanmar, and Maldives. The company was formerly known as Merck Limited and changed its name to Procter & Gamble Health Limited in May 2019. The company was incorporated in 1967 and is headquartered in Mumbai, India. Procter & Gamble Health Limited is a subsidiary of Procter & Gamble Overseas India B.V.

How the Company Makes Money

Procter & Gamble Health Ltd. generates revenue primarily through the sale of its healthcare products, which include over-the-counter medications, vitamins, and dietary supplements. The company benefits from Procter & Gamble's extensive distribution network, brand strength, and marketing capabilities to reach a broad consumer base. Key revenue streams include sales through retail channels, online platforms, and partnerships with healthcare providers and pharmacies. Additionally, PGHL may engage in strategic collaborations and licensing agreements to expand its product offerings and market reach, further contributing to its revenue.

Procter & Gamble Health Ltd. Financial Statement Overview

Summary

Procter & Gamble Health Ltd. exhibits a strong financial position across all verticals. The income statement reflects robust profitability and growth, while the balance sheet indicates excellent financial stability with low leverage. The cash flow statement is positive, with strong cash generation capabilities. The company is well-positioned for future growth, though there is room for improvement in cost management and operational efficiency.

Income Statement

Procter & Gamble Health Ltd. demonstrates strong profitability with a consistent increase in net profit margin and EBIT margin over the years. The company has shown a healthy revenue growth rate of 7.42% in the most recent year, indicating robust sales performance. However, the gross profit margin has declined slightly, suggesting increased cost pressures. Overall, the income statement reflects a solid financial performance with room for improvement in cost management.

Balance Sheet

The balance sheet of Procter & Gamble Health Ltd. is very strong, characterized by a low debt-to-equity ratio of 0.014, indicating minimal leverage and financial risk. The return on equity is impressive at 58.21%, showcasing efficient use of shareholder funds to generate profits. The equity ratio is healthy, reflecting a strong capital structure. Overall, the balance sheet is robust, with excellent financial stability and low risk.

Cash Flow

The cash flow statement shows a positive trajectory with strong free cash flow to net income ratio of 0.95, indicating efficient cash generation relative to net income. The operating cash flow to net income ratio is slightly lower at 0.82, suggesting room for improvement in operational efficiency. The free cash flow growth rate is exceptionally high, but this is due to a low base effect. Overall, the cash flow position is solid, with potential for enhanced operational cash flow management.

Breakdown	TTM	Dec 2025	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	12.18B	12.46B	11.51B	12.30B	10.92B	9.91B
Gross Profit	7.69B	6.84B	8.21B	8.68B	7.25B	6.52B
EBITDA	3.59B	4.38B	3.07B	3.43B	2.81B	2.64B
Net Income	2.51B	3.13B	2.01B	2.29B	1.93B	1.77B
Balance Sheet
Total Assets	7.94B	7.94B	7.94B	11.01B	8.94B	9.86B
Cash, Cash Equivalents and Short-Term Investments	2.06B	1.89B	2.44B	4.53B	3.19B	4.64B
Total Debt	76.20M	76.20M	95.60M	120.00M	28.30M	76.10M
Total Liabilities	2.57B	2.57B	2.56B	3.50B	2.77B	2.82B
Stockholders Equity	5.37B	5.37B	5.38B	7.51B	6.16B	7.04B
Cash Flow
Free Cash Flow	459.90M	1.67B	2.07B	1.94B	1.32B	1.95B
Operating Cash Flow	492.20M	1.76B	2.28B	2.36B	1.70B	2.47B
Investing Cash Flow	-500.00K	24.40M	-68.70M	-215.00M	-255.40M	-322.70M
Financing Cash Flow	-1.34B	-2.35B	-4.18B	-984.70M	-2.89B	-3.87B

Procter & Gamble Health Ltd. Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 6275.75
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:PGHL, the sentiment is Positive. The current price of 6275.75 is below the 20-day moving average (MA) of 6343.71, above the 50-day MA of 6204.15, and above the 200-day MA of 5555.37, indicating a neutral trend. The MACD of 18.62 indicates Positive momentum. The RSI at 48.92 is Neutral, neither overbought nor oversold. The STOCH value of 56.54 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IN:PGHL.

Procter & Gamble Health Ltd. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
PGHL	77 Outperform	₹104.17B	34.66	―	2.94%	2.37%	23.22%
ZYDUSWELL	73 Outperform	₹153.21B	46.84	6.12%	0.25%	10.63%	7.53%
JYOTHYLAB	68 Neutral	₹114.09B	31.22	18.07%	1.12%	1.59%	-2.52%
SYMPHONY	67 Neutral	₹61.92B	37.08	27.99%	1.44%	-6.43%	-20.90%
SURYAROSNI	65 Neutral	₹62.41B	21.67	14.06%	1.49%	-8.69%	-20.94%
EVEREADY	57 Neutral	₹28.33B	34.00	17.88%	0.39%	5.32%	16.91%
Sector *	62 Neutral	$20.33B	14.63	-3.31%	3.23%	1.93%	-12.26%